In addition, we show for the first time that the presence of STAT3/STAT5B mutations is associated in LGLL with reduced numbers of most normal residual blood-leukocyte subsets, independently of the specific LGLL cell-lineage involved, with important clinical consequences including a shorter time-to-therapy. This evidence concerns the gene STAT3 and T-cell large granular lymphocyte leukemia.